Table 3 BEDiso converted to clinically applicable dose fractionation schedules to achieve at least 90% local control at 2 years of CRC metastases
Tumor location | No prior Chemo | Prior Chemo | ||
|---|---|---|---|---|
Lung | 99 ± 15 Gy10 BEDiso | 3 × 9 Gy @ 65% | 211 ± 19 Gy10 BEDiso | 3 × 15 Gy @ 65% |
8 × 5 Gy @ 65% | 5 × 10.5 Gy @ 65% | |||
Liver | 187 ± 19 Gy10 BEDiso | 3 × 14 Gy @ 65% | 300 ± 39 Gy10 BEDiso | 3 × 18 Gy @ 65% |
5 × 10 Gy @ 65% | 5 × 13 Gy @ 65% | |||